Summary
The provided claim is about U.S. list price and March 2024 pricing, which is not addressed in the supplied FDA prescribing information excerpts; therefore the claim cannot be verified against the label.
Category Scores
Accurate Statements
Unsupported Statements
Ozempic’s U.S. list price was $935.77 for a 1-month supply in March 2024.
The supplied FDA-approved prescribing information excerpts do not contain any information about U.S. list price, pricing date (March 2024), or month-supply cost.
Contradictions
Important Omissions
Comparison of the stated U.S. list price ($935.77) and the time period (March 2024) to any labeling-supported pricing information.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The mismatch is informational (pricing) rather than a direct drug safety claim, and the provided labeling excerpts do not address pricing.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Claim concerns pricing that is not supported by the supplied FDA prescribing information.
Suggested Improvement
Limit claims to content present in the prescribing information; if pricing is needed, provide a source outside the label or exclude the pricing claim from the label-based evaluation.